WebNov 19, 2024 · GSK3640254 (GSK’254) GSK3640254 by GlaxoSmithKline/ViiV Healthcare is a next-generation, small-molecule potential HIV treatment drug which acts as a Maturation Inhibitor (MI) that acts during the last step of the HIV lifecycle. GSK3640254 binds to HIV-1 Gag, inhibiting the final protease-mediated cleavage event between … WebHIV: Phase II: HIV maturation inhibitor: GSK1265744 ^ cabotegravir: HIV (400 mg/ml formulation) Phase I: HIV integrase inhibitor: VH3739937 ^ HIV: Phase I: HIV maturation inhibitor: VH4004280 ^ HIV: ... you can report adverse events to GSK/ViiV by selecting your region and market, here. Connect with us. ViiV Healthcare. 980 Great West Road ...
HIV GSK
WebAverage GSK'254 concentrations lay above the efficacy target of 1.10 ng/mL with the 40-, 80-, 140-, and 200-mg doses. At day 11 in part 1 of the trial, the maturation inhibitor resistance mutation A364A/V emerged in 4 of 6 participants taking 200 mg of GSK'254 once daily for 10 days. In 1 of 4 people with this emergent mutation, phenotypic ... boeing compliance jobs
GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an
WebMar 9, 2024 · ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, presented positive data from its phase IIa proof-of-concept study of the investigational maturation inhibitor GSK3640254 (GSK’254). The study showed the antiviral activity of GSK’254, establishing a … WebAug 31, 2024 · GSK3640254 is an HIV-1 maturation inhibitor (MI) that exhibits significantly improved antiviral activity toward a range of clinically relevant polymorphic variants with … WebJan 18, 2024 · HIV-1 maturation inhibitors (MIs) offer a novel mechanism of action and potential for use in HIV-1 treatment. Prior MIs displayed clinical efficacy but were … boeing competitor